Journal of Food Biochemistry,
Год журнала:
2024,
Номер
2024, С. 1 - 19
Опубликована: Март 11, 2024
Saffron,
indicated
as
“the
red
gold,”
is
an
extraordinary
spice
with
a
unique
aroma
and
organoleptic
properties
that
largely
diffused
in
food
preparation
well
traditional
medicine
many
countries
of
the
world.
In
last
years,
several
studies
have
considered
this
for
CNS-based
disorders
showing
its
potential
usefulness.
review,
we
role
saffron
nutraceutical
management
most
CNS
diseases
considering
important
oxidative
stress
on
pathogenesis
such
diseases.
fact,
recent
findings
support
crucial
different
suggesting
antioxidants.
Preclinical
clinical
evidence
efficacy
physiopathological
pathways
involved
were
discussed
pharmacological
activities
beneficial
effects
pathological
models
or
small
trials.
Due
to
low
toxicity
significant
inflammation
ability
modulate
mitochondrial
function,
extracts
their
constituents
appear
be
promising
active
compounds
area.
Further
investigations
are
progress
assess
safety
preventive
agents
nutraceuticals
adjuvant
used
combinations
other
therapeutic
approaches.
Saffron
antioxidant
activity
can
useful
improving
quality
life
patients
suffering
from
conditions
related
CNS.
summarized
more
standardized
products
valuable
instrument
well-being
due
multiple
targets
health
brain
tissues.
The World Journal of Biological Psychiatry,
Год журнала:
2022,
Номер
24(5), С. 333 - 386
Опубликована: Окт. 6, 2022
Objectives
The
primary
objectives
of
these
international
guidelines
were
to
provide
a
global
audience
clinicians
with
(a)
series
evidence-based
recommendations
for
the
provision
lifestyle-based
mental
health
care
in
clinical
practice
adults
Major
Depressive
Disorder
(MDD)
and
(b)
implementation
considerations
that
may
be
applicable
across
range
settings.Methods
Recommendations
associated
gradings
based
on
systematic
literature
searches
published
research
as
well
expertise
taskforce
members.
focus
was
eight
lifestyle
domains:
physical
activity
exercise,
smoking
cessation,
work-directed
interventions,
mindfulness-based
stress
management
therapies,
diet,
sleep,
loneliness
social
support,
green
space
interaction.
following
electronic
bibliographic
databases
searched
articles
prior
June
2020:
PubMed,
EMBASE,
Cochrane
Library
(Cochrane
Database
Systematic
Reviews,
Central
Register
Controlled
Trials
(CENTRAL),
Methodology
Register),
CINAHL,
PsycINFO.
Evidence
grading
level
evidence
specific
MDD
risk
bias,
accordance
World
Federation
Societies
Biological
Psychiatry
criteria.Results
Nine
formed.
highest
ratings
improve
use
relaxation
techniques,
therapies
(Grade
2).
Interventions
related
diet
recommended,
but
lower
strength
3).
regarding
cessation
support
expert
opinion.
Key
included
need
input
from
allied
professionals
networks
implement
this
type
approach,
importance
partnering
such
behaviour
change
deliver
interventions
using
biopsychosocial-cultural
framework.Conclusions
Lifestyle-based
are
recommended
foundational
component
Disorder,
where
other
can
added
or
used
combination.
findings
further
address
existing
gaps
efficacy
research,
especially
emerging
approaches
(e.g.
space,
interventions)
data
limited.
Further
work
is
also
needed
develop
innovative
delivery
models
care,
training
care.
JAMA,
Год журнала:
2024,
Номер
332(2), С. 141 - 141
Опубликована: Июнь 10, 2024
Importance
Approximately
9%
of
US
adults
experience
major
depression
each
year,
with
a
lifetime
prevalence
approximately
17%
for
men
and
30%
women.
Observations
Major
is
defined
by
depressed
mood,
loss
interest
in
activities,
associated
psychological
somatic
symptoms
lasting
at
least
2
weeks.
Evaluation
should
include
structured
assessment
severity
as
well
risk
self-harm,
suspected
bipolar
disorder,
psychotic
symptoms,
substance
use,
co-occurring
anxiety
disorder.
First-line
treatments
specific
psychotherapies
antidepressant
medications.
A
network
meta-analysis
randomized
clinical
trials
reported
cognitive
therapy,
behavioral
activation,
problem-solving
interpersonal
brief
psychodynamic
mindfulness-based
psychotherapy
all
had
medium-sized
effects
symptom
improvement
over
usual
care
without
(standardized
mean
difference
[SMD]
ranging
from
0.50
[95%
CI,
0.20-0.81]
to
0.73
0.52-0.95]).
21
medications
small-
placebo
(SMD
0.23
0.19-0.28]
fluoxetine
0.48
0.41-0.55]
amitriptyline).
Psychotherapy
combined
medication
may
be
preferred,
especially
more
severe
or
chronic
depression.
greater
treatment
than
alone
(SMD,
0.30
0.14-0.45])
0.33
0.20-0.47]).
When
initial
not
effective,
second-line
includes
changing
medication,
adding
second
antidepressant,
augmenting
nonantidepressant
which
have
equal
likelihood
success
based
on
meta-analysis.
Collaborative
programs,
including
systematic
follow-up
outcome
assessment,
improve
effectiveness,
1
reporting
significantly
compared
0.42
0.23-0.61]).
Conclusions
Relevance
Effective
first-line
forms
20
Close
monitoring
improves
the
success.
Neuroscience & Biobehavioral Reviews,
Год журнала:
2024,
Номер
158, С. 105561 - 105561
Опубликована: Янв. 26, 2024
The
use
of
probiotics,
prebiotics,
synbiotics
or
fermented
foods
can
modulate
the
gut-brain
axis
and
constitute
a
potentially
therapeutic
intervention
in
psychiatric
disorders.
This
systematic
review
aims
to
identify
current
evidence
regarding
these
interventions
treatment
patients
with
DSM/ICD
diagnoses.
Forty-seven
articles
from
42
studies
met
inclusion
criteria.
Risk
bias
was
assessed
all
included
studies.
Major
depression
most
studied
disorder
(n=19
studies).
Studies
frequently
focused
on
schizophrenia
(n=11)
bipolar
(n=5)
there
were
limited
anorexia
nervosa
(n=4),
ADHD
(n=3),
Tourette
(n=1),
insomnia
PTSD
(n=1)
generalized
anxiety
(n=1).
Except
MDD,
does
not
clarify
role
probiotics
prebiotics
mental
illness.
Several
point
an
improvement
immune
inflammatory
profile
(e.g.
CRP,
IL6),
which
may
be
relevant
mechanism
action
response
identified
Future
research
should
consider
lifestyle
dietary
habits
as
possible
confounders
that
influence
inter-individual
response.
Neuropharmacology,
Год журнала:
2023,
Номер
226, С. 109418 - 109418
Опубликована: Янв. 6, 2023
Psychiatric
disorders
associated
with
psychological
trauma,
stress
and
anxiety
are
a
highly
prevalent
increasing
cause
of
morbidity
worldwide.
Current
therapeutic
approaches,
including
medication,
effective
in
alleviating
symptoms
posttraumatic
disorder
(PTSD),
at
least
some
individuals,
but
have
unwanted
side-effects
do
not
resolve
underlying
pathophysiology.
After
period
stagnation,
there
is
renewed
enthusiasm
from
public,
academic
commercial
parties
designing
developing
drug
treatments
for
these
disorders.
Here,
we
aim
to
provide
snapshot
the
current
state
this
field
that
written
neuropharmacologists,
also
practicing
clinicians
interested
lay-reader.
introducing
currently
available
treatments,
summarize
recent/ongoing
clinical
assessment
novel
medicines
PTSD,
grouped
according
primary
neurochemical
targets
their
potential
produce
acute
and/or
enduring
effects.
The
evaluation
putative
targeting
monoamine
(including
psychedelics),
GABA,
glutamate,
cannabinoid,
cholinergic
neuropeptide
systems,
amongst
others,
discussed.
We
emphasize
importance
clinically
assessing
new
medications
based
on
firm
understanding
neurobiology
stemming
rapid
advances
being
made
neuroscience.
This
includes
harnessing
neuroplasticity
bring
about
lasting
beneficial
changes
brain
rather
than
–
as
many
transient
attenuation
symptoms,
exemplified
by
combining
psychotropic/cognitive
enhancing
drugs
psychotherapeutic
approaches.
conclude
noting
other
emerging
trends
promising
phase
development.
Journal of Midwifery & Women s Health,
Год журнала:
2023,
Номер
68(4), С. 421 - 429
Опубликована: Июнь 24, 2023
Abstract
There
has
been
a
steady
increase
in
people
with
symptoms
of
depression
over
the
past
several
years
(since
2011).
The
further
stress
and
early
part
COVID‐19
pandemic
was
accompanied
by
an
unmet
mental
health
needs.
Many
have
turned
to
complementary
alternative
medicine
(CAM)
therapies
such
as
bright‐light
therapy,
yoga,
meditation,
dietary
supplements
like
St.
John's
wort
or
folic
acid.
reliability
evidence
for
use
CAM
remained
low.
are
few
randomized
controlled
trials
(RCTs)
current
literature
poor
methodology
many
that
available.
This
state
science
review
examines
published
guidelines,
meta‐analyses,
systematic
reviews,
RCTs
regarding
management
depression.
Nutrients,
Год журнала:
2023,
Номер
15(17), С. 3859 - 3859
Опубликована: Сен. 4, 2023
Depressive
disorders
pose
significant
challenges
to
global
public
health,
necessitating
effective
prevention
and
management
strategies.
Notably,
the
occurrence
of
suicide
frequently
coincides
with
depressive
episodes.
Suicide
is
as
a
paramount
health
concern
that
demands
efficacious
preventive
Current
psychiatric
approaches
heavily
rely
on
pharmacological
interventions
but
have
had
limited
success
in
addressing
burden
mental
issues.
Suboptimal
nutrition,
its
impact
neuroendocrine
system,
has
been
implicated
underlying
pathology
disorders.
Folate,
group
water-soluble
compounds,
plays
crucial
role
various
central
nervous
system
functions.
Depressed
individuals
often
exhibit
low
levels
serum
red
blood
cell
folate.
Multiple
studies
systematic
reviews
investigated
efficacy
folic
acid
derivative,
L-methylfolate,
which
can
cross
blood–brain
barrier,
stand-alone
or
adjunct
therapies
for
depression.
Although
findings
mixed,
available
evidence
generally
supports
use
these
compounds
depressed
individuals.
Recent
established
links
between
one-carbon
cycle,
folate–homocysteine
balance,
immune
function,
glutamate
excitation
via
NMDA
(N-methyl-D-aspartate)
receptors,
gut
microbiome
eubiosis
mood
regulation.
These
provide
insights
into
complex
neurobiological
mechanisms
effects
folate
related
Through
comprehensive
review
existing
literature,
this
study
aims
advance
our
understanding
therapeutic
potential
depression
treatment.
It
also
seeks
explore
their
suicidal
tendencies
shed
light
involved,
leveraging
latest
discoveries
research.